TARA - NASDAQ

Protara Therapeutics, Inc.

TARA·NASDAQ

$4.22

-1.2%

HealthcareBiotechnology

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$162.85M

EPS-1.3400

P/E Ratio-3.15

Earnings Date07/30/2026

209.47M

Assets

15%

3Y+85.0%

5Y+3.0%

10Y+381.0%

13.06M

Total Liabilities

-9%

3Y+16.0%

5Y+234.0%

10Y+157.0%

196.41M

Total Equity

18%

3Y+92.0%

5Y-1.0%

10Y+411.0%

Protara Therapeutics, Inc. Funding & Solvency Profile

TARA · NASDAQ

Current Assets

Cash & Cash Equivalents49.66M

Net Receivables1.26M

Inventory0.00

Other Current Assets2.69M

Total Current Assets160 M

Non-Current Assets

Property, Plant & Equipment3.93M

Goodwill & Intangible Assets0.00

Long-Term Investments0.00

Other Non-Current Assets46.03M

Total Non-Current Assets50 M

Total Assets

209.47M

Financial Health Analysis

Current Ratio

14.58x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.07x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

149 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

76% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Protara Therapeutics, Inc. Balance Sheet

TARA • NASDAQ

Protara Therapeutics, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013	Dec 2012
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	49.7M	162.8M	39.6M	24.1M	35.7M	168.6M	6.2M	19.4M	21.2M	36.4M	40M	68.8M	2.8M	2.4M
Short-Term Investments	105.9M	7.5M	26M	60.2M	55.5M	0.0	0.0	2.5M	21M	4.9M	25.2M	14.8M	2.4M	5.1M
Cash & Short-Term Investments	155.6M	170.3M	65.6M	84.4M	91.2M	168.6M	6.2M	21.9M	42.1M	41.3M	65.3M	83.6M	5.2M	7.5M
Net Receivables	1.3M	0.0	242K	486K	634K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Accounts Receivables	1.3M	0.0	242K	486K	634K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Inventory	0.0	0.0	0.0	1.2M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Prepaids	0.0	1.9M	2.8M	1.2M	1.2M	735K	78K	1.4M	0.0	0.0	0.0	0.0	61K	152K
Other Current Assets	2.7M	2K	37K	-1M	34K	102K	716K	0.0	22.3M	6.4M	26.6M	15.8M	78K	41K
Total Current Assets	159.5M	172.2M	68.7M	86.1M	93.1M	169.4M	7M	23.2M	43.5M	42.8M	66.6M	84.6M	5.3M	7.7M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	3.9M	5.3M	6.6M	7.9M	8.9M	2.3M	459K	263K	259K	372K	224K	83K	62K	79K
Goodwill	0.0	0.0	0.0	0.0	29.5M	29.5M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Intangible Assets	0.0	3.2M	2.7M	84K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Goodwill & Intangible Assets	0.0	3.2M	2.7M	84K	29.5M	29.5M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Long-Term Investments	0.0	0.0	0.0	17.9M	39.5M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax Assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	267K	0.0
Other Non-Current Assets	46M	772K	1M	1.3M	1.6M	1.9M	122K	22K	240K	393K	706K	114K	0.0	0.0
Total Non-Current Assets	50M	9.3M	10.2M	27.1M	79.5M	33.7M	581K	285K	499K	765K	930K	197K	329K	79K
Other Assets	0.0	0.0	0.0	0.0	0.0	0.0	-581K	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Assets	209.5M	181.5M	79M	113.3M	172.6M	203.2M	7M	23.5M	44M	43.5M	67.5M	84.8M	5.7M	7.8M
LIABILITIES
CURRENT LIABILITIES
Total Payables	3.5M	4.4M	2.4M	1.6M	954K	1.1M	716K	441K	0.0	0.0	0.0	0.0	666K	469K
Accounts Payable	3.5M	4.4M	2.4M	1.6M	954K	914K	716K	441K	0.0	0.0	0.0	0.0	399K	469K
Other Payables	0.0	0.0	0.0	0.0	0.0	159K	0.0	0.0	0.0	0.0	0.0	0.0	267K	0.0
Accrued Expenses	0.0	2.9M	620K	694K	688K	224K	4K	2.6M	1.3M	1.1M	0.0	641K	419K	81K
Short Term Debt	1.2M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	20K	0.0	0.0	0.0	5.1M	0.0
Capital Lease Obligations (Current)	0.0	1.1M	983K	917K	855K	88K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax Payables	0.0	0.0	0.0	0.0	41K	159K	0.0	0.0	0.0	0.0	0.0	0.0	267K	0.0
Deferred Revenue	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-28.1K	0.0	0.0	0.0	2.9M	0.0
Other Current Liabilities	6.2M	2.5M	2.1M	2.5M	1.8M	1.5M	-137K	0.0	7.9M	3.9M	4.1M	1.7M	677K	654K
Total Current Liabilities	10.9M	11M	6.1M	5.7M	4.3M	2.9M	583K	3.1M	9.2M	5.1M	4.1M	2.3M	9.8M	1.2M
NON-CURRENT LIABILITIES
Deferred Revenue (Non-Current)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.9M
Total Non-Current Liabilities	2.1M	3.4M	4.5M	5.5M	6.4M	999K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.9M
Capital Lease Obligations	2.1M	4.5M	5.5M	6.4M	7.2M	1.1M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Liabilities	13.1M	14.3M	10.6M	11.2M	10.7M	3.9M	583K	3.1M	9.2M	5.1M	4.1M	2.3M	9.8M	4.2M
SHAREHOLDERS' EQUITY
Treasury Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	202.3M	0.0	0.0	0.0	0.0	0.0
Preferred Stock	0.0	0.0	0.0	0.0	0.0	0.0	18.5M	21.5M	21.5M	548K	0.0	84.8M	96.4M	90.3M
Common Stock	54K	35K	11K	11K	11K	11K	3K	19K	18K	17K	16K	16K	0.0	0.0
Additional Paid-In Capital	498.7M	412.1M	268.7M	262.7M	256.1M	246M	213.4M	209.4M	203M	198.2M	194.7M	0.0	0.0	0.0
Retained Earnings	-302.4M	-245M	-200.4M	-160M	-94M	-46.8M	-225.5M	-210.5M	-189.7M	-159.8M	-131.3M	-109.9M	-100.5M	-86.7M
Accumulated Other Comprehensive Income/Loss	90K	2K	-31K	-688K	-211K	0.0	3K	5K	-14K	-565K	-11K	-12K	0.0	1K
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	0.0	0.0	-3K	0.0	-202.3M	0.0	0.0	107.5M	0.0	0.0
Total Stockholders' Equity	196.4M	167.1M	68.3M	102.1M	161.9M	199.2M	6.4M	20.4M	34.7M	38.4M	63.4M	82.5M	-4.1M	3.6M
Total Equity	196.4M	167.1M	68.3M	102.1M	161.9M	199.2M	6.4M	20.4M	34.7M	38.4M	63.4M	82.5M	-4.1M	3.6M
SUMMARY
Total Liabilities & Equity	209.5M	181.5M	79M	113.3M	172.6M	203.2M	7M	23.5M	44M	43.5M	67.5M	84.8M	5.7M	7.8M
Total Investments	105.9M	7.5M	26M	78.1M	95M	0.0	0.0	2.5M	21M	4.9M	25.2M	14.8M	2.4M	5.1M
Total Debt	3.4M	4.5M	5.5M	6.4M	7.2M	1.1M	0.0	0.0	20K	0.0	0.0	0.0	5.1M	0.0
Net Debt	-46.3M	-158.3M	-34.1M	-17.7M	-28.5M	-167.5M	-6.2M	-19.4M	-21.2M	-36.4M	-40M	-68.8M	2.2M	-2.4M
Shares Outstanding	38,581,863	38,581,863	38,581,863	38,581,863	38,581,863	38,581,863	38,581,863	38,581,863	38,581,863	38,581,863	38,581,863	38,581,863	38,581,863	38,581,863

SEC Filings

TARA - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
S-3 S-3 N/A	May 14, 2026	May 14, 2026		View Filing
10-Q 10-Q 2026 Q1 Q1	May 13, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 13, 2026	May 13, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 28, 2026	June 12, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 30, 2026	March 30, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 10, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	March 10, 2026	March 10, 2026	2026	View Filing
8-K 8-K 2026 N/A	February 24, 2026	February 23, 2026	2026	View Filing
8-K 8-K 2025 N/A	December 15, 2025	December 15, 2025	2025	View Filing
8-K 8-K 2025 N/A	December 08, 2025	December 04, 2025	2025	View Filing

Showing 1 to 10 of 207 filings

Related Guides

Blog Categories

Continue your TARA research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.